In vivo, the use of TAAR1 agonists lowered hyperlocomotion in pharmacologic, i.e., cocaine-induced, and genetic, i.e., DAT-knockout (KO), models of hyperdopaminergia (Revel et al., 2011, 2013), allegedly a hallmark of psychosis (Howes and Kapur, 2009). This evidence concerns the gene TAAR1 and psychotic disorder.